MUSTGROW BIOLOGICS CORP. Financials MustGrow Biologics Corp. Canadian Securities Exchange
Equities
MGRO
CA62822A1030
Biotechnology & Medical Research
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| - CAD | -.--% |
|
+6.74% | -28.57% |
| Apr. 23 | MustGrow Biologics Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Jan. 22 | MustGrow Biologics Corp.(TSXV:MGRO) dropped from S&P/TSX Venture Composite Index | CI |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Capitalization 1 | 48.39 | 190.7 | 175.8 | 66.39 | 51.64 |
| Enterprise Value (EV) 1 | 48.39 | 190.7 | 175.8 | 66.39 | 51.64 |
| P/E ratio | -13.9 x | -57 x | -32.2 x | -129 x | 10 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | 14,814 x | 27,129 x | - | 184 x |
| EV / Revenue | - | 14,814 x | 27,129 x | - | 184 x |
| EV / EBITDA | - | - | - | - | - |
| EV / FCF | - | - | - | - | - |
| FCF Yield | - | - | - | - | - |
| Price to Book | - | 22.5 x | - | - | - |
| Nbr of stocks (in thousands) | 38,715 | 47,784 | 49,659 | 51,464 | 51,641 |
| Reference price 2 | 1.250 | 3.990 | 3.540 | 1.290 | 1.000 |
| Announcement Date | 4/29/21 | 4/26/22 | 4/27/23 | 4/23/24 | - |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Net sales 1 | - | 0.0129 | 0.00648 | - | 0.2805 |
| EBITDA | - | - | - | - | - |
| EBIT 1 | - | -3.011 | - | - | -5.3 |
| Operating Margin | - | -23,396.35% | - | - | -1,889.3% |
| Earnings before Tax (EBT) | - | -3.064 | - | - | - |
| Net income 1 | -3.31 | -3.064 | - | - | -5.138 |
| Net margin | - | -23,806.37% | - | - | -1,831.55% |
| EPS 2 | -0.0900 | -0.0700 | -0.1100 | -0.0100 | 0.1000 |
| Free Cash Flow | - | - | - | - | - |
| FCF margin | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 4/29/21 | 4/26/22 | 4/27/23 | 4/23/24 | - |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 0.00145 | 0.00372 | 0.00131 | - | - | - | - | - | 0.001 | 0.001 | 0.001 | 0.2775 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -1.082 | -0.9996 | -1.422 | -2.172 | -1.084 | -1.116 | - | - | - | -1.194 | -1.144 | -2.044 | -0.9175 |
| Operating Margin | - | -68,937.24% | -38,212.63% | -165,780.15% | - | - | - | - | - | -119,400% | -114,400% | -204,400% | -330.63% |
| Earnings before Tax (EBT) | -1.096 | -1.01 | -1.422 | - | - | - | - | - | - | - | - | - | - |
| Net income 1 | -1.096 | -1.01 | -1.422 | -2.133 | -1.002 | -1.046 | - | - | - | -1.152 | -1.103 | -2.004 | -0.8785 |
| Net margin | - | -69,631.72% | -38,212.63% | -162,821.37% | - | - | - | - | - | -115,200% | -110,300% | -200,400% | -316.58% |
| EPS 2 | -0.0200 | -0.0200 | -0.0300 | -0.0400 | -0.0200 | -0.0200 | -0.0200 | -0.0400 | 0.0700 | 0.0200 | 0.0200 | 0.0400 | 0.0200 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 4/26/22 | 5/26/22 | 8/26/22 | 11/29/22 | 4/27/23 | 5/26/23 | 8/29/23 | 11/29/23 | 4/23/24 | - | - | - | - |
1CAD in Million2CAD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | -56.8% | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share | - | 0.1800 | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - |
| Announcement Date | 4/29/21 | 4/26/22 | 4/27/23 | 4/23/24 | - |
1CAD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
1
Average target price
-
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- MGRO Stock
- MGRO Stock
- Financials MustGrow Biologics Corp.
